Analyser av RaySearch Laboratories

Q4 beat our sales estimates and came in line with our EBIT forecast.

RaySearch delivered a strong Q4, with record sales above consensus estimates and record EBIT, also above consensus estimates.

Redeye presents its preview of RaySearch’s Q4 2025 results due on February 12.

RaySearch’s Q3 increases our confidence in its potential for profitable sales growth, with accelerating sales drivers as we move into 2026.

RaySearch delivers incredibly strong results with record sales, a 96% gross margin, and an EBIT margin well above expectations (and its own ...

Redeye presents its preview of RaySearch’s Q3 2025 results due on Friday, November 7.

Redeye returns with a more in-depth take on the Q2 report.

Redeye notes a soft Q2 on both sales and EBIT, and we expect a negative share price reaction today of around -5%.

Redeye leaves its preview of RaySearch’s Q2 2025 results due on Friday, August 8.

Redeye returns with a more in-depth take on the Q1 report.

Redeye notes an exceptionally strong Q1 with record sales.

Redeye shares its preview for RaySearch’s Q1 2025 report, due May 9.

Redeye initiates coverage of RaySearch, a software company offering treatment planning systems for radiotherapy clinics.